Cisplatin and Etoposide for Oesophageal Cancer
Author Information
Author(s): TC Kok, A Van der Gaast, J Dees, WMH Eykenboom, H Van Overhagen, G Stoter, HW Tilanus, TAW Splinter
Primary Institution: University Hospital Rotterdam
Hypothesis
The study aims to determine the activity and toxicity of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus.
Conclusion
The combination of cisplatin and etoposide resulted in a 48% overall response rate in patients with advanced oesophageal cancer.
Supporting Evidence
- The overall response rate was 48%, including five complete responses and 26 partial responses.
- Median time to progression was 7 months.
- Two patients experienced toxic deaths due to neutropenic sepsis.
Takeaway
Doctors tested two medicines, cisplatin and etoposide, to see if they could help people with a type of throat cancer, and many patients got better.
Methodology
A phase II trial was conducted with 73 patients receiving a combination of cisplatin and etoposide, with response and toxicity evaluated after treatment.
Potential Biases
Potential bias due to lack of a control group and the observational nature of the study.
Limitations
The study had a small sample size and included patients with varying degrees of disease progression.
Participant Demographics
Patients were mostly male, aged between 41 and 76, with a performance status of WHO 0-2.
Statistical Information
Confidence Interval
95% CI 35-60%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website